AC Immune SA
From Verify.Wiki
 | |
| | |
| AC Immune SA | |
|---|---|
| Type | Public |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Lausanne, Switzerland |
| Key people | Andrea Pfeifer (Co-Founder & CEO), Jean-Fabien Monin (CFO), Andreas Muhs (CSO) [1] |
| Investors | Dietmar Hopp |
| Number of employees | 62 [2] |
AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. The company’s technology platforms create antibodies, small molecules, and vaccines to address a broad spectrum of neurodegenerative indications. It offers its therapies to address Alzheimer disease and neurodegenerative diseases, such as Parkinson’s, Down syndrome, and glaucoma.
AC Immune SA was founded in 2003 and is based in Lausanne, Switzerland. [3]
Contents
History
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| July 04, 2020 | HedgeFundRisk | Hedge Funds Have Never Been This Bullish On AC Immune SA (ACIU) - Yahoo Finance https://t.co/WM3pKgiAQ7 https://t.co/7luLFfZDyn |
| June 27, 2020 | HealthcareBeat | Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC $ACIU https://t.co/eUyFLJvS9o |
| June 26, 2020 | EdgarInsider | SEC Form 6-K filed by $ACIU AC Immune SA https://t.co/P1ozeNlJUw |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- ↑ http://www.acimmune.com/en/senior-management-team/
- ↑ http://www.nasdaq.com/markets/ipos/company/ac-immune-sa-995734-81000
- ↑ http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=22309440
Top Authors
Verification history
1,311 days ago- View all verifications
